<DOC>
	<DOCNO>NCT00004202</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Drugs RSR13 may make tumor cell sensitive radiation therapy . PURPOSE : Phase II trial study effectiveness combination chemotherapy , radiation therapy , RSR13 treat patient stage III non-small cell lung cancer remove surgery .</brief_summary>
	<brief_title>Combination Chemotherapy , Radiation Therapy , RSR13 Treating Patients With Stage III Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine one year survival rate , two year survival rate , median survival rate patient locally advance unresectable non-small cell lung cancer treat paclitaxel carboplatin follow radiotherapy plus RSR13 . II . Determine complete partial response rate progression free interval chest ( radiation portal ) patient regimen . III . Determine time disease progression outside radiation portal patient regimen . IV . Determine toxic effect adverse event associate regimen patient . OUTLINE : This multicenter study . Induction chemotherapy : Patients receive paclitaxel IV 3 hour carboplatin IV 30 minute every 3 week 2 course . Radiotherapy : Beginning 3 4 week induction chemotherapy , patient receive RSR13 IV 30 minute , follow fractionate radiotherapy 5 time weekly 6-7 week . Patients follow monthly 2 month every 3 month thereafter disease progression death . PROJECTED ACCRUAL : A total 46-48 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Efaproxiral</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm locally advanced unresectable stage IIIA IIIB nonsmall cell lung cancer ( NSCLC ) , include : Squamous cell carcinoma OR Adenocarcinoma ( include bronchoalveolar cell ) OR Large cell anaplastic carcinoma ( include giant clear cell ) OR Poorly differentiate NSCLC No small cell carcinoma No distant metastasis Measurable evaluable disease chest xray , CT , MRI scan Tumors adjacent vertebral body eligible gross disease radiation boost field No pleural effusion ( ) exudative , bloody , cytologically malignant No asymptomatic brain metastasis CT MRI scan PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 12 week Hematopoietic : Granulocyte count least 2,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL ( transfusion epoetin alfa allow ) Hepatic : Bilirubin le 1.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : No uncontrolled serious cardiac disease No active congestive heart failure , unstable angina , pericardial effusion , arrhythmia Pulmonary : FVC FEV1 least 50 % Resting exercise SaO2 room air least 90 % pulse oximetry Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active concurrent malignancy within past 5 year , except : Nonmelanomatous skin cancer Carcinoma situ cervix No serious medical psychiatric illness would preclude compliance No active serious infection No concurrent clinically significant peripheral neuropathy No prior significant allergic reaction drug contain Cremophor ( e.g. , cyclosporine vitamin K ) No great 10 % weight loss past 3 month PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior biologic therapy No concurrent immunotherapy ( radiotherapy ( RT ) RSR13 administration ) Chemotherapy : No prior systemic chemotherapy No concurrent chemotherapy ( RT RSR13 administration ) Endocrine therapy : No concurrent hormonal therapy ( RT RSR13 administration ) Radiotherapy : No prior radiotherapy thorax Surgery : At least 1 week since prior diagnostic thoracoscopy OR At least 3 week since prior thoracotomy recover No prior total surgical resection Other : At least 3 week since prior investigational agent device No prior RSR13</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>